CHICAGO, May 31 (Reuters) - Revolution Medicine's (RVMD.O), opens new tab experimental pancreatic cancer pill doubled survival compared with chemotherapy and improved symptoms enough that some ...

An experimental pancreatic cancer drug has ignited hope in a field desperate for new treatments. Compared with traditional chemotherapy, a pill called daraxonrasib nearly doubled the survival time of ...

A pancreatic cancer drug more than four decades in the making has cracked one of the most stubbornly lethal cancers, extending people’s lives and keeping their tumors in check for twice as long as ...

A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer. “While not ...

Exclusive: People from deprived and minority ethnic backgrounds have better access to device than for previous technologies The rollout of a “life-changing” artificial pancreas on the NHS for people ...

A new drug for pancreatic cancer is showing promise in early testing. Daraxonrasib is a daily pill designed to block cancer signals linked to the RAS gene. It has now finished an early-stage clinical ...

Kerry Breen is a news editor at CBSNews.com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital. She covers current events, ...

An experimental drug that could be a breakthrough in the treatment of one of the deadliest known cancers is driving demand at clinics while awaiting full government approval. Daraxonrasib, a drug that ...

RAS oncoproteins, once considered undruggable, are now being successfully targeted by new drugs like daraxonrasib, showing dramatically improved survival in pancreatic cancer patients. Personalized ...

The drug's benefits significantly outweigh its adverse effects, researchers say Survival time is roughly doubled with daraxonrasib vs standard chemotherapy Drug targets a mutation found in 90% of ...

CHICAGO — Patients who develop acute pancreatitis while being treated with GLP-1 receptor agonists (RAs) show lower rates of recurrence if they continue with the treatment than if they discontinue, ...

Ben Sasse says he’s still alive thanks to "providence, prayer and a miracle drug." The 54-year-old former U.S. senator from Nebraska was told he had four months to live at most last December when he ...